To investigate clinical trial outcome measures for USH2A-related retinal disease, patients with molecularly confirmed biallelic USH2A mutations (n = 56, average age 40 years, range 15–66 at first visit) were retrospectively assessed. This evidence concerns the gene USH2A and Abnormal retinal morphology.